T2 Biosystems announced on September 20, 2024, that it has successfully defended its European Patent No. 3 443 124 against an opposition filed by bioMerieux and other undisclosed parties. The patent, challenged in May 2023, covers the company's method for amplifying target nucleic acid characteristic of pathogens in whole blood samples.The European Patent Office's Opposition Division held a public hearing on September 19, 2024, ruling in favor of T2 Biosystems and maintaining the company's strong IP position on direct-from-whole blood pathogen detection. This patent is a crucial component of T2 Biosystems' intellectual property portfolio protecting their proprietary detection method.Chairman and CEO John Sperzel emphasized the decision's significance in reinforcing confidence in their IP portfolio's broad scope. The company remains committed to defending its patents while advancing its technology, commercial platform, and product pipeline in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes.

T2 Biosystems announced on September 20, 2024, that it has successfully defended its European Patent No. 3 443 124 against an opposition filed by bioMerieux and other undisclosed parties. The patent, challenged in May 2023, covers the company's method for amplifying target nucleic acid characteristic of pathogens in whole blood samples.The European Patent Office's Opposition Division held a public hearing on September 19, 2024, ruling in favor of T2 Biosystems and maintaining the company's strong IP position on direct-from-whole blood pathogen detection. This patent is a crucial component of T2 Biosystems' intellectual property portfolio protecting their proprietary detection method.Chairman and CEO John Sperzel emphasized the decision's significance in reinforcing confidence in their IP portfolio's broad scope. The company remains committed to defending its patents while advancing its technology, commercial platform, and product pipeline in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes.